176 related articles for article (PubMed ID: 32048933)
1. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.
Pagel JM; Othus M; Garcia-Manero G; Fang M; Radich JP; Rizzieri DA; Marcucci G; Strickland SA; Litzow MR; Savoie ML; Spellman SR; Confer DL; Chell JW; Brown M; Medeiros BC; Sekeres MA; Lin TL; Uy GL; Powell BL; Bayer RL; Larson RA; Stone RM; Claxton D; Essell J; Luger SM; Mohan SR; Moseley A; Erba HP; Appelbaum FR
JCO Oncol Pract; 2020 Jun; 16(6):e464-e475. PubMed ID: 32048933
[TBL] [Abstract][Full Text] [Related]
2. Comparison of autologous hematopoietic cell transplantation and chemotherapy as postremission treatment in non-M3 acute myeloid leukemia in first complete remission.
Usuki K; Kurosawa S; Uchida N; Yakushiji K; Waki F; Matsuishi E; Kagawa K; Furukawa T; Maeda Y; Shimoyama M; Ago H; Yamano Y; Yano S; Fujishima N; Takamatsu Y; Eto T; Hidaka M; Matsuoka H; Fukuda T
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):444-51. PubMed ID: 22999942
[TBL] [Abstract][Full Text] [Related]
3. Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Østgård LSG; Lund JL; Nørgaard JM; Nørgaard M; Medeiros BC; Nielsen B; Nielsen OJ; Overgaard UM; Kallenbach M; Marcher CW; Riis AH; Sengeløv H
Biol Blood Marrow Transplant; 2018 Feb; 24(2):314-323. PubMed ID: 29051022
[TBL] [Abstract][Full Text] [Related]
4. Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.
Mawad R; Gooley TA; Sandhu V; Lionberger J; Scott B; Sandmaier BM; O'Donnell P; Becker PS; Petersdorf S; Dorcy KS; Hendrie P; Sorror ML; Walter RB; Deeg HJ; Appelbaum FR; Estey EH; Pagel JM
J Clin Oncol; 2013 Nov; 31(31):3883-8. PubMed ID: 24062388
[TBL] [Abstract][Full Text] [Related]
5. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Passweg JR; Labopin M; Christopeit M; Cornelissen J; Pabst T; Socié G; Russel N; Yakoub-Agha I; Blaise D; Gedde-Dahl T; Labussière-Wallet H; Malladi R; Forcade E; Maury S; Polge E; Lanza F; Gorin NC; Mohty M; Nagler A
Biol Blood Marrow Transplant; 2020 Apr; 26(4):659-664. PubMed ID: 31759159
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
Stelljes M; Beelen DW; Braess J; Sauerland MC; Heinecke A; Berning B; Kolb HJ; Holler E; Schwerdtfeger R; Arnold R; Spiekermann K; Müller-Tidow C; Serve HL; Silling G; Hiddemann W; Berdel WE; Büchner T; Kienast J;
Haematologica; 2011 Jul; 96(7):972-9. PubMed ID: 21459795
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
Weisdorf DJ; Millard HR; Horowitz MM; Hyare PS; Champlin R; Ho V; Mielcarek M; Rezvani A; Stockerl-Goldstein K; Khoury HJ; De Lima M; Saber W; Sandmaier B; Zhang MJ; Eapen M
Cancer; 2017 Jun; 123(11):2025-2034. PubMed ID: 28117884
[TBL] [Abstract][Full Text] [Related]
8. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission.
Kurosawa S; Yamaguchi T; Uchida N; Miyawaki S; Usuki K; Watanabe M; Yamashita T; Kanamori H; Tomiyama J; Nawa Y; Yano S; Takeuchi J; Yakushiji K; Sano F; Uoshima N; Yano T; Nannya Y; Moriuchi Y; Miura I; Takaue Y; Fukuda T
Biol Blood Marrow Transplant; 2011 Mar; 17(3):401-11. PubMed ID: 20667478
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
10. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
Michelis FV; Gupta V; Zhang MJ; Wang HL; Aljurf M; Bacher U; Beitinjaneh A; Chen YB; DeFilipp Z; Gale RP; Kebriaei P; Kharfan-Dabaja M; Lazarus HM; Nishihori T; Olsson RF; Oran B; Rashidi A; Rizzieri DA; Tallman MS; de Lima M; Khoury HJ; Sandmaier BM; Weisdorf D; Saber W;
Cancer; 2017 Jun; 123(11):2035-2042. PubMed ID: 28117898
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.
Ustun C; Le-Rademacher J; Wang HL; Othus M; Sun Z; Major B; Zhang MJ; Storrick E; Lafky JM; Chow S; Mrózek K; Attar EC; Nand S; Bloomfield CD; Cripe LD; Tallman MS; Appelbaum F; Larson RA; Marcucci G; Roboz GJ; Uy GL; Stone RM; Jatoi A; Shea TC; de Lima M; Foran JM; Sandmaier BM; Litzow MR; Erba HP; Hurria A; Weisdorf DJ; Artz AS
Leukemia; 2019 Nov; 33(11):2599-2609. PubMed ID: 31073153
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials.
Heinicke T; Krahl R; Kahl C; Cross M; Scholl S; Wolf HH; Hähling D; Hegenbart U; Peter N; Schulze A; Florschütz A; Schmidt V; Reifenrath K; Zojer N; Junghanss C; Sayer HG; Maschmeyer G; Späth C; Hochhaus A; Fischer T; Al-Ali HK; Niederwieser D
Ann Hematol; 2021 Sep; 100(9):2387-2398. PubMed ID: 34232360
[TBL] [Abstract][Full Text] [Related]
13. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.
Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Kanamori H; Usuki K; Yamashita T; Watanabe M; Yakushiji K; Yano S; Nawa Y; Taguchi J; Takeuchi J; Tomiyama J; Nakamura Y; Miura I; Kanda Y; Takaue Y; Fukuda T
Blood; 2011 Feb; 117(7):2113-20. PubMed ID: 21106987
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
15. Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission.
Yano S; Yokoyama H; Yanada M; Mori J; Aoki J; Ohashi K; Kanomori H; Ozawa Y; Sawa M; Nakamae H; Eto T; Ohta S; Tanaka J; Ichinohe T; Atsuta Y; Takami A
Bone Marrow Transplant; 2019 Dec; 54(12):2004-2012. PubMed ID: 31152148
[TBL] [Abstract][Full Text] [Related]
16. The evolving concept of indications for allogeneic hematopoietic cell transplantation during first complete remission of acute myeloid leukemia.
Yanada M
Bone Marrow Transplant; 2021 Jun; 56(6):1257-1265. PubMed ID: 33686251
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
[TBL] [Abstract][Full Text] [Related]
18. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.
Basara N; Schulze A; Wedding U; Mohren M; Gerhardt A; Junghanss C; Peter N; Dölken G; Becker C; Heyn S; Kliem C; Lange T; Krahl R; Pönisch W; Fricke HJ; Sayer HG; Al-Ali H; Kamprad F; Niederwieser D;
Leukemia; 2009 Apr; 23(4):635-40. PubMed ID: 19151786
[TBL] [Abstract][Full Text] [Related]
19. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
20. Early Allogeneic Transplantation Favorably Influences the Outcome of Pediatric Acute Myeloid Leukemia-A Retrospective Study in a Single Center Over 2 Decades.
Lo TY; Wang YL; Jaing TH; Chang TY; Wen YC; Chiu CC; Hsiao YW; Chen SH
Transplant Proc; 2024; 56(1):201-210. PubMed ID: 38245493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
